Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2017 | 12-2006 | 12-2005 | |
| Cash Flows From Operating Activities | ||||
| Net Income | 20,118 | N/A | N/A | N/A |
| Depreciation Amortization | 548 | N/A | N/A | N/A |
| Accounts receivable | -17,751 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 5,212 | N/A | N/A | N/A |
| Other Working Capital | -11,954 | N/A | N/A | N/A |
| Other Operating Activity | 13,832 | 0 | 0 | 0 |
| Operating Cash Flow | $10,005 | $N/A | $N/A | $N/A |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -12,723 | N/A | N/A | N/A |
| Investing Cash Flow | $-12,723 | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | ||||
| Debt Repayment | -182 | N/A | N/A | N/A |
| Common Stock Issued | 9,900 | N/A | N/A | N/A |
| Other Financing Activity | -736 | 0 | 0 | 0 |
| Financing Cash Flow | $8,982 | $N/A | $N/A | $N/A |
| Beginning Cash Position | 6,346 | N/A | N/A | N/A |
| End Cash Position | 12,610 | N/A | N/A | N/A |
| Net Cash Flow | $6,264 | $N/A | $N/A | $N/A |
| Free Cash Flow | ||||
| Operating Cash Flow | 10,005 | N/A | N/A | N/A |
| Capital Expenditure | -12,732 | N/A | N/A | N/A |
| Free Cash Flow | -2,727 | 0 | 0 | 0 |